Physician profile
Trisha A Garrett
NPI 1619261369
$2,814.33
in general payments reported to CMS, 2019-2025
37 companies · $370 in 2025
The $370 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $412 · 2021: $587 · 2022: $79.83 · 2023: $290 · 2024: $437 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,065 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,065.18 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $363.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $345.28 | 2019-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $275.38 | 2019-2024 | Airsupra |
| Lilly USA, LLC | $229.75 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $170.50 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $163.82 | 2019-2024 | |
| Abbvie INC. | $108.95 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $88.57 | 2021-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $86.05 | 2024-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $73.25 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.99 | 2019-2021 | |
| Mylan Specialty L.P. | $70.37 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.58 | 2019-2024 | Jardiance |
| Philips North America LLC | $60.22 | 2021-2022 | |
| Grifols USA, LLC | $51.22 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $49.98 | 2019-2021 | |
| Eisai INC. | $49.67 | 2020-2021 | |
| Celgene Corporation | $42.56 | 2019 | |
| Viatris Specialty LLC | $37.21 | 2025 | Yupelri |
| Ironwood Pharmaceuticals, INC | $36.93 | 2020-2021 | |
| Abiomed | $35.95 | 2024 | Impella |
| Axsome Therapeutics, INC. | $35.32 | 2022-2023 | Auvelity |
| Exact Sciences Corporation | $34.55 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $34.52 | 2019-2023 | Xarelto |
| Kowa Pharmaceuticals America, INC. | $30.39 | 2024-2025 | Zoryve |
| Amarin Pharma, INC. | $30.01 | 2021 | |
| Allergan, INC. | $22.05 | 2019 | |
| Sonex Health, INC. | $19.20 | 2025 | Sx-One Microknife |
| Abbott Laboratories | $18.19 | 2025 | Freestyle Libre 3 |
| Incyte Corporation | $17.66 | 2021 | |
| Ardelyx, INC. | $16.32 | 2025 | Ibsrela |
| Shire North American Group INC | $16.10 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.99 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.09 | 2020 | |
| Jazz Pharmaceuticals INC. | $12.98 | 2021 | |
| Dexcom, INC. | $12.83 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trisha Garrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.